David L. Lacey - 11 Jun 2026 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Reporting relationship: Director
Issuer ticker: RCUS
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 16:28:06 UTC
Prior SEC filing: 15 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Carolyn Tang, Attorney-in-Fact

Key filing fact

David L. Lacey filed Form 4 for Arcus Biosciences, Inc. (RCUS) on 12 Jun 2026.

Key facts

This page summarizes David L. Lacey's Form 4 filing for Arcus Biosciences, Inc. (RCUS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 16:28.

Change

Previous filing in this sequence was filed on 15 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001734422 Primary reporting owner

Lacey David L.

Relationship: Director
Address: C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD
Signature: /s/ Carolyn Tang, Attorney-in-Fact
Signature date: 12 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCUS transaction

Common Stock

Award

Transaction value
Shares: +5,700
Change %: +8%
Price: $0.000000^*
Shares after: 76,652
Date: 11 Jun 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCUS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +16,900
Change %
Price: $0.000000^*
Shares after: 16,900
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Stock Option (Rights to Buy)
Underlying amount: 16,900
Exercise price: $23.30
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents the grant of restricted stock units that vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control.

Footnote F2

The option will vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders of the issuer. The option will become fully vested and exercisable in the event the Company is subject to a change in control.